STOCK TITAN

Trulieve to Ring The Closing Bell at the New York Stock Exchange as First U.S. Cannabis Company Listed on the NYSE

Trulieve (NYSE: TRLV) will ring The Closing Bell® at the New York Stock Exchange at 4:00 p.m. ET on August 18, 2026, to celebrate its June 10, 2026 NYSE listing.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Trulieve (NYSE: TRLV) will ring The Closing Bell® at the New York Stock Exchange at 4:00 p.m. ET on August 18, 2026, to celebrate its June 10, 2026 NYSE listing. According to the company, Trulieve is the first U.S. cannabis company listed on the NYSE.

Founder and CEO Kim Rivers will lead the ceremony with the board and executive team. Trulieve reports operating 207 medical dispensaries, over 5,000 employees, and 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia, with $109 million in operating cash flow in the first half of 2026 and $325 million in cash at Q2-end.

Loading...
Loading translation...
Argus Aug 18 session 5 alerts
+2.43% close to close 1.9x rel. volume Open Argus
Details

News Market Reaction – TRLV

$1.95B Market Cap

On Aug 18, the day this news came out, TRLV closed 2.43% above the previous close. Our momentum scanner recorded 5 alerts in the available session data. Relative volume reached 1.9x the daily average during tracking.

Data tracked by StockTitan Argus for the Aug 18 session.

Key Figures

NYSE listing date: June 10, 2026 Medical dispensaries: 207 dispensaries Employees: More than 5,000 employees +5 more
NYSE listing date
June 10, 2026
Trulieve NYSE listing
Medical dispensaries
207 dispensaries
Across Florida, Georgia, Pennsylvania, and West Virginia
Employees
More than 5,000 employees
Company highlights
Cultivation and production capacity
3.5 million square feet
Across four U.S. states
Federal rescheduling
Schedule III
State-licensed medical marijuana rescheduling in April 2026
Cash flow from operations
$109 million
First half of 2026
Cash
$325 million
Ending the second quarter of 2026
Texas public health regions
All 11 public health regions
Retail pipeline under the Texas Compassionate Use Program

Historical Context

5 past events · Latest: Aug 11
5 events
  1. Aug 11

    Corporate redomicile

    24h Move
    -2.7%

    Completed redomicile from British Columbia to Delaware and continued NYSE trading

  2. Aug 07

    Q2 earnings report

    24h Move
    -2.8%

    Revenue declined year-over-year while GAAP net loss included Harvest deconsolidation

  3. Aug 05

    Conference participation

    24h Move
    -5.1%

    Announced CEO participation in Canaccord Genuity's 46th Annual Growth Conference

  4. Jul 16

    Dispensary opening

    24h Move
    -2.5%

    Announced Marco Island medical cannabis dispensary opening for July 24

  5. Jul 10

    Earnings call scheduling

    24h Move
    -2.5%

    Scheduled second-quarter results conference call for August 7

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

schedule iii, dea
2 terms
schedule iii regulatory
"Following state licensed medical marijuana rescheduling to Schedule III in April 2026"
A Schedule III classification is a regulatory category for drugs and substances that have a recognized medical use but a moderate risk of dependence or abuse, placing them between higher-risk controlled drugs and over-the-counter medicines. For investors, this matters because it shapes how a product can be manufactured, prescribed, marketed and distributed — affecting potential sales, regulatory hurdles, labeling requirements and legal exposure in the market; think of it as a middle level of control that influences commercial access and compliance costs.
dea regulatory
"all 207 Trulieve medical dispensaries were registered with the U.S. Drug Enforcement"
The DEA is the U.S. Drug Enforcement Administration, the federal agency that enforces laws on controlled substances and issues licenses for handling regulated drugs. It matters to investors because DEA actions—such as granting or revoking registrations, issuing enforcement actions, or scheduling substances—can directly affect a company’s ability to manufacture, distribute, research, or sell certain pharmaceuticals, similar to how a traffic controller can speed up or stop movement on a busy road.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TALLAHASSEE, Fla., Aug. 18, 2026 /PRNewswire/ -- Trulieve Cannabis Corp. (NYSE: TRLV) ("Trulieve" or "the Company"), a leading and top-performing medical cannabis company in the U.S., announced it will ring The Closing Bell® at the New York Stock Exchange (NYSE) at 4:00 P.M. eastern time today, August 18, 2026, in celebration of its NYSE listing on June 10, 2026.

Trulieve logo

Founder and Chief Executive Officer Kim Rivers will be joined by members of Trulieve's Board of Directors and executive leadership team to commemorate the occasion. The bell-ringing ceremony marks a historic achievement for Trulieve as the first U.S. cannabis company listed on the NYSE and reflects the Company's leadership position in the U.S. cannabis industry.

"Ringing The Closing Bell at the New York Stock Exchange is an incredible honor and a proud moment for everyone who has contributed to Trulieve's success," said Kim Rivers, Trulieve's Chief Executive Officer. "Our NYSE listing represents the culmination of years of disciplined execution, operational excellence, and a commitment to creating long-term value for our shareholders. We are excited to celebrate this milestone alongside our team as we continue to build on our successes and capitalize on the opportunities ahead."

Company Highlights:

  • Scale: Trulieve is the largest medical cannabis operator in the U.S., with 207 medical dispensaries, more than 5,000 employees, and 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia.
  • Federal rescheduling: Following state licensed medical marijuana rescheduling to Schedule III in April 2026, all 207 Trulieve medical dispensaries were registered with the U.S. Drug Enforcement Administration (DEA), with inspections completed in Florida, Pennsylvania, and West Virginia.
  • Georgia: Medical marijuana program expansion under SB 220 accelerated patient enrollment and enabled the launch of new Modern Flower and Roll One branded vape and inhalable flower products across retail dispensaries and independent pharmacies.
  • Texas: Trulieve has initial production capacity ready for final inspection and retail pipeline spanning all 11 public health regions to serve patients under the Texas Compassionate Use Program (TCUP) upon receipt of final licensure.
  • Financial Strength: Trulieve generated $109 million in cash flow from operations in the first half of 2026, ending the second quarter with $325 million in cash.

A video of the bell-ringing ceremony will be available for viewing on the NYSE's website at www.nyse.com/bell.

About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established medical marijuana operations in Florida, Georgia, Pennsylvania, and West Virginia. Driven by a core mission to expand access to cannabis, Trulieve serves customers with innovative, high-quality branded products and exceptional experiences. With scaled operations in attractive markets and targeted expansion through its hub strategy, Trulieve is poised for accelerated growth. Trulieve is listed on the NYSE under the symbol TRLV. For more information, please visit Trulieve.com.

Facebook: @Trulieve   Instagram: @Trulieve   X: @Trulieve

Investor and Media Contact
Christine Hersey, Chief Corporate Affairs and Strategy Officer
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trulieve-to-ring-the-closing-bell-at-the-new-york-stock-exchange-as-first-us-cannabis-company-listed-on-the-nyse-302853436.html

SOURCE Trulieve Cannabis Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why is Trulieve (NYSE: TRLV) ringing the NYSE Closing Bell on August 18, 2026?

Trulieve is ringing the NYSE Closing Bell to celebrate its NYSE listing on June 10, 2026. According to Trulieve, this ceremony marks its status as the first U.S. cannabis company listed on the NYSE and recognizes its leadership in the U.S. medical cannabis industry.

When did Trulieve (TRLV) become the first U.S. cannabis company listed on the NYSE?

Trulieve’s shares began trading on the New York Stock Exchange on June 10, 2026. According to Trulieve, this listing made it the first U.S. cannabis company on the NYSE and is described as the culmination of years of disciplined execution and operational focus.

What is the scale of Trulieve’s operations mentioned in the August 18, 2026 NYSE bell announcement?

Trulieve reports operating 207 medical dispensaries and employing more than 5,000 people. According to Trulieve, it also has 3.5 million square feet of cultivation and production capacity across Florida, Georgia, Pennsylvania, and West Virginia, positioning it as a large U.S. medical cannabis operator.

What financial metrics did Trulieve (NYSE: TRLV) highlight around its NYSE bell ringing in August 2026?

Trulieve highlighted generating $109 million in cash flow from operations in the first half of 2026. According to Trulieve, the company ended the second quarter of 2026 with $325 million in cash, underscoring available liquidity to support its medical cannabis operations and expansion plans.

How did federal rescheduling affect Trulieve’s medical cannabis dispensaries in 2026?

Following state licensed medical marijuana rescheduling to Schedule III in April 2026, all 207 Trulieve medical dispensaries were registered with the DEA. According to Trulieve, inspections have been completed in Florida, Pennsylvania, and West Virginia, reflecting regulatory alignment for its existing medical cannabis footprint.

What growth initiatives did Trulieve (TRLV) describe in Georgia and Texas in its NYSE bell announcement?

In Georgia, Trulieve cited program expansion under SB 220 and new Modern Flower and Roll One products. According to Trulieve, it also has initial production capacity and a retail pipeline ready in Texas under the Compassionate Use Program, pending final licensure and inspection.

Keep reading